Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy
Key findings
Pivotal Phase 3 trial leading to Luxturna approval. First FDA-approved gene therapy using AAV2 for inherited retinal disease. Established AAV2 as gold standard for retinal applications.